HealthQuill US
AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.
Drugs Health Pharma

AstraZeneca’s medicine to treat a type of breast cancer gets US nod

AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.

Read More
Atara Biotherapeutics’ Ebvallotm therapy, for treating patients with a rare cancer that occurs after stem cell transplantation, got rejected by the US drug regulator.
Drugs Health Pharma

US drug regulator rejects Atara Biotherapeutics’ rare cancer therapy

Atara Biotherapeutics’ Ebvallotm therapy, for treating patients with a rare cancer that occurs after stem cell transplantation, got rejected by the US drug.

Read More
US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which is under trial, for treating chronic kidney diseases.
Drugs Health Pharma

Vertex, China’s Zai to develop, commercialise kidney disease drug

US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which.

Read More
Novo Nordisk A/S, a Danish pharmaceutical company, has expanded its agreement with US-based Valo Health Inc., almost to double the number of drugs to be jointly developed, according to a statement.
Drugs Health Medical

Novo Nordisk, Valo expand pact to include obesity, diabetic drugs

Novo Nordisk A/S, a Danish pharmaceutical company, has expanded its agreement with US-based Valo Health Inc., almost to double the number of drugs.

Read More
China’s WuXi Biologics, a clinical research organization, has granted global rights to US-based Candid Therapeutics to use the company’s synthetic antibody to fight cancer for an upfront payment of $925 million.
Drugs Medical Pharma

WuXi Biologics sells global rights to cancer antibody to Candid for $925m

China’s WuXi Biologics, a clinical research organization, has granted global rights to US-based Candid Therapeutics to use the company’s synthetic antibody to fight.

Read More
The European Union regulators have greenlighted AstraZeneca’s drug to treat an advanced form of non-small cell lung cancer after it reduced the death rate by 84%.
Drugs Medical Pharma

EU greenlights AstraZeneca’s non-small cell lung cancer drug

The European Union regulators have greenlighted AstraZeneca’s drug to treat an advanced form of non-small cell lung cancer after it reduced the death.

Read More
Humacyte Global, Inc., a US-based bioengineering company, got the US regulator’s nod for its product Symvess, a surgical implant to replace a patient’s damaged blood vessel after a traumatic injury.
Drugs Health Medical Pharma

Humacyte’s tissue-engineered blood vessel for vascular trauma gets nod

Humacyte Global, Inc., a US-based bioengineering company, got the US regulator’s nod for its product Symvess, a surgical implant to replace a patient’s.

Read More
fizer Inc.’s combination drug to treat a type of metastatic colorectal cancer has been approved by the US drug regulator, according to a company statement.
Drugs Medical Pharma

Pfizer’s drug to treat metastatic colorectal cancer gets US approval

fizer Inc.’s combination drug to treat a type of metastatic colorectal cancer has been approved by the US drug regulator, according to a.

Read More
Eli Lilly and Company will invest $3 billion in the US to expand its manufacturing facility to meet a rise in demand for medicines in the areas of diabetes and obesity.
Uncategorized

Eli Lilly to expand US facility as demand soars for diabetes, obesity medicines

Eli Lilly and Company will invest $3 billion in the US to expand its manufacturing facility to meet a rise in demand for.

Read More
The US regulator has granted a breakthrough therapy designation to British-Swedish AstraZeneca and Japan’s Daiichi Sankyo experimental drug for treating a certain type of lung cancer.
Drugs Medical Pharma

AstraZeneca, Daiichi’s trial drug for lung cancer, gets US regulator’s nod

The US regulator has granted a breakthrough therapy designation to British-Swedish AstraZeneca and Japan’s Daiichi Sankyo experimental drug for treating a certain type.

Read More